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Identity 
Other names: MGC22357; RAGE 
HGNC (Hugo): AGER 
Location: 6p21.32 
 
Figure 1. Schematic of human chromosome 6. 
DNA/RNA 
Description 
The human AGER (RAGE) gene lies within the major 
histocompatibility complex class III region on 
chromosome 6, which contains genes involved in 
immune responses, such as TNFalpha, lymphotoxin, 
complement components and homeobox gene HOX12. 
It comprises 11 exons and 10 introns, and a 5' flanking 
region that regulates its transcription. The resulting 
transcribed mRNA of ~1.4 kb with a short 3'UTR is 
alternatively spliced, and nearly twenty isoforms have 
been identified in different tissues such as lung, liver, 
kidney, smooth muscle, endothelial cells and brain. The 
different RAGE gene splice variants have been named 
RAGE, RAGE_v1 to RAGE_v19 according to the 
Human Gene Nomenclature Committee. RAGE is 
composed of a number of distinct protein domains; a 




signal peptide (aa 1-22), followed by three 
immunoglobulin-like domains, a V-type domain, (aa 
23-116) and two C type domains (C1: aa 124-221 and 
C2: 227-317), a single transmembrane domain (aa 343-
363), and a short cytoplasmic domain (aa 364-404) 
necessary for signaling. The prevalent isoforms of 
RAGE are full length RAGE, RAGE_v1 or endogenous 
secretory (es RAGE) which lacks the cytosolic and 
transmembrane domains and therefore can be secreted 
into the extracellular space, and N-terminal truncated 
RAGE (RAGE_v2) which lacks N-terminal V domain 
and therefore cannot bind ligands. RAGE_v2 does not 
form mature protein. Through its ability to scaveng 
RAGE ligands, soluble RAGE isoforms (sRAGE) are 
believed to act a decoy receptor by regulating signal ng 
mediated by activation of full length RAGE. 
Expression of isoforms is tissue specific, suggesting 
tight tissue-specific regulation of expression. sRAGE 
can also be formed by ectodomain cleavage by 
ADAM10/MMP9.  
A number of NF-kappaB sites have been identified in 
the RAGE 5' regulatory region. In addition, 
transcription is also controlled by other pro-
inflammatory transcription factors such as SP-1 and 
AP-2. 
At least 30 polymorphisms are known, most of which 
are single nucleotide polymorphisms (SNP). A Gly to 
Ser change at an N-glycosylation sequon at position 82, 
and two 5' flanking polymorphisms at position -374 
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Protein 
Description 
The V and C1 domains in the extracellular region of 
RAGE form an integrated structural unit, while C2 is 
fully independent, attached to VC1 through a flexible 
linker. RAGE was originally identified as a receptor f r 
advanced glycation end products, but it also interacts 
with other structurally unrelated ligands including 
HMGB1, several members of the S100 family, 
amyloid-beta peptide, transthyretin and beta2 integrin 
Mac-1. By virtue of its multi-domain structure and 
ability to recognize different classes of ligands, RAGE 
behaves as a pattern recognition receptor (PRR) akin to 
innate immune receptors such as Toll-like receptors 
(TLRs) in orchestrating immune responses. However, 
unlike other PRRs that predominantly bind exogenous 
ligands, RAGE binds endogenous ligands, especially 
those considered to be damage associated molecular 
pattern molecules (DAMPs). AGEs, HMGB1, Abeta 
peptides, S100B, S100A1, S100A2 and S100A5 bind to 
the V domain, S100A12 binds to V-C1 domains, and 
S100A6 interacts with V-C2 domain. Studies on S100 
protein-RAGE interactions also suggest that 
multimerization of ligand and receptor occurs and that 
formation of these higher ordered complexes may be 
essential for signal transduction. In addition to 
contribution by protein interaction domains, post-
translational modifications such as glycosylation of the 
receptors, or acetylation or phosphorylation of ligands 
could also play important roles in defining specificity 
of interactions, multimerization and downstream 
signaling. RAGE has two N-glycosylation sites on the
V-domain and both sites are occupied by complex and 
hybrid or high mannose N-glycans. A subpopulation is 
modified by carboxylated glycans, which promote 
interaction with HMGB1, S100A8/S100A9 and 
S100A12. In addition, the quaternary structure of 
RAGE might also account for the diversity of ligand 
recognition. Though the cytoplasmic domain lacks 
endogenous kinase activity or any other known 
signaling motif, studies indicate that the cytoplasmic 
domain is essential for intracellular signaling. 
Expression 
RAGE is highly expressed during embryonic 
development, especially in the brain, but levels 
decrease in adult tissues. RAGE is found at low levels 
in neurons, endothelial cells, mononuclear phagocytes, 
smooth muscle cells, and constitutively expressed at 
high levels in the lung. 
Localisation 
- Full length: membrane: single pass type I membrane 
protein.  
- Isoforms: secreted. 
 
 
Figure 2. Schematic of RAGE protein and its domains. 
RAGE is a multi-ligand receptor consisting of three Ig-domains 
(V, C1 and C2), a transmembrane domain and a cytosolic tail 
required for RAGE-mediated intracellular signaling. The V and 
C1 domains in the extracellular region of RAGE form an 
integrated structural unit, while C2 is fully independent, 
attached to VC1 through a flexible linker. Many ligands bind to 
the V domain, while some also interact with the V-C1 or V-C2 
domains. The V domain has N-glycosylation sites both of which 
are modified. Ligand binding activates multiple signaling 
pathways and regulates gene expression through the 
transcription factors NF-kappaB, CREB and SP1 (From 
Rauvala H, Rouhiainen A. Biochim Biophys Acta. 2010 Jan-
Feb;1799(1-2):164-70. Reproduced with permission from 
publishers). 
Function 
Normal physiological functions of RAGE include 
embryonal neuronal growth, myogenesis, mobilization 
of dendritic cells, activation and differentiation of T 
cells, stem cell migration and osteoclast maturation. 
HMGB1 interaction of RAGE results in stimulation of 
myogenesis. RAGE mediates trophic and toxic effects 
of S100B on embryonal neurons, and promotes neurite 
outgrowth and neuronal regeneration promoted by 
HMGB1. RAGE also plays an important role in the 
regulation of osteoclast maturation and function, ad 
bone remodeling. 
Ligand interaction promotes activation of intracellular 
signaling pathways including the MAPK pathway, 
RAC-1 and CDC42, NADPH oxidase, PI3 kinase and  
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JAK/STAT pathway, and activation of NF-kappaB. 
RAGE expression is induced in inflammatory settings, 
since its transcription is controlled by several 
transcription factors as mentioned above. Thus a 
positive feed-forward loop evolves in ligand rich 
inflammatory settings, perpetuating the pathology. 
sRAGE is believed to regulate signaling mediated by 
activation of full length RAGE. Binding of RAGE to 
HMGB1 induces RAGE shedding by ADAM10 
metalloprotease, thus possibly representing another 





RAGE is constitutively expressed in human gastric 
carcinoma cell lines, and poorly differentiated human 
gastric carcinomas preferentially express RAGE. 
Strong RAGE expression is seen in cells at the invasive 
edge of tumors and correlates with invasion and lymph 
node metastasis. Studies in Chinese population show 
that Gly82Ser polymorphism on RAGE is associated 
with increased risk for gastric cancer. 
Colon cancer 
Note 
RAGE expression is increased in advanced colon 
tumors. Co-expression of RAGE and its ligands 
HMGB1 and S100P is strongly associated with 
invasion and metastasis of human colorectal cancer. 
RAGE appears to be at the interface of inflammation 
and colon cancer, since RAGE deficient mice are 
resistant to the onset of colitis associated colon cancer. 
Pancreatic cancer 
Note 
Expression of RAGE is strongest in pancreatic cancer 
cells with high metastatic ability, and RAGE may play 
an important role in the viability of pancreatic tumor 
cells against stress-induced apoptosis. RAGE ligand 
S100P is overexpressed in pancreatic cancer. 
Prostate cancer 
Note 
RAGE and ligands are highly expressed on prostate 
cancer cell lines, untreated prostate cancer tissue and 
hormone-refractory prostate cancer tissue, and RAGE 
promotes growth and invasion of prostate cancer cells 
in response to ligand activation. 
Oral squamous cell cancer 
Note 
RAGE expression closely associates with histologic 
differentiation, invasiveness, angiogenesis and 
recurrence of oral squamous cell carcinoma. 
 
Common bile duct cancer 
Note 
RAGE is expressed on human biliary cancer cells, and 
expression correlates with their invasive ability. 
Glioma 
Note 
HMGB1/RAGE signaling pathways promote the 
growth and migration of human glioblastoma cells. 
Inhibition of RAGE-HMGB1 interactions decreases 
growth and metastases of gliomas in mice. 
Skin cancer 
Note 
RAGE is expressed in human melanoma cells and 
promotes ligand-dependent growth and invasion. 
RAGE null mice are resistant to the onset of 
inflammation mediated skin tumors in mice. 
Lung cancer 
Note 
RAGE, as well as its ligands, is highly expressed in 
normal lung, but unlike other cancers, RAGE is 
markedly reduced in human lung carcinomas. Down-
regulation correlates with advanced tumor stages, 
suggesting that RAGE may have tumor suppressive 
functions in lung cancer. 
Tumor microenvironment 
Note 
Many RAGE ligands are expressed and secreted not 
only by cancer cells but also by cells within the tumor 
microenvironment, including myeloid derived cells and 
vascular cells. These ligands interact with the receptor 
in both autocrine and paracrine manners, promoting 
tumor growth, invasion, angiogenesis and metastasis. 
Inflammation and immune responses 
Note 
RAGE and its ligands are highly enriched in immune 
and inflammatory foci and their interaction promotes 
upregulation of inflammatory cytokines, adhesion 
molecules and matrix metalloproteinases. They are 
therefore implicated in many inflammatory conditions 
including colitis and arthritis. RAGE is upregulated in 
synovial tissue macrophages and its ligands are 
abundant in inflamed synovial tissue. Activation leads 
to increased stimulation of chondrocytes and 
synoviocytes, promoting ongoing inflammation and 
autoimmunity in arthritis. RAGE mediates HMGB1 
activation of dendritic cells in response to DNA 
containing immune complexes, contributing to 
autoimmune pathogenesis. Blockade of RAGE 
interactions suppresses myelin basic protein induce 
experimental autoimmune encephalomyelitis. 
Inhibition of RAGE-ligand interactions or RAGE 
deletion protects mice from septic shock induced by  
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caecal ligation and puncture. RAGE null mice are also 




RAGE, as a receptor for advanced glycation end 
products and other pro-inflammatory ligands, 
contributes to micro and macrovascular changes in 
diabetes. RAGE over-expression in transgenic mice is 
associated with increased vascular injury, diabetic 
nephropathy and neuropathy, while RAGE deletion 
confers partial protection from these diabetes-
associated changes. 
Atherosclerosis and ischemia 
Note 
Increased RAGE expression is found in endothelial 
cells in non-diabetic patients with peripheral occlusive 
vascular disease. sRAGE reduces atherosclerotic 
lesions and inflammation in normoglycemic Apo E null 
mice, and reduced neointima expansion in wild type 
mice following femoral artery injury. Studies on 
ischemia-reperfusion injury of the heart in wild type 
and RAGE null mice show that infarct size and severity 
of tissue damage is dependent on HMGB1-RAGE 
interactions following necrotic cell death. 
Neuronal degeneration 
Note 
RAGE is expressed on neurons, microglia and 
endothelial cells in the brain, and binds the multimeric 
form of amyloid-beta peptide. Binding leads to 
activation of NADPH oxidase, generation of reactive 
oxygen species, activation of NF-kappaB and CREB, 
and upregulation of cytokines and chemokines, thus 
promoting neuroinflammation. The associated up-
regulation and release of other RAGE ligands such as 
HMGB1 and S100 proteins further amplifies this 
cascade, leading to neuronal degeneration. sRAGE has 
been shown to be beneficial in animal models of 
Alzheimer's disease. RAGE null mice are also partially 
protected from diabetes-induced loss of neuronal 
function. 
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